Pervenio Lung RS Test for Early Stage Lung Cancer

Share this content:

Life Technologies Corporation announced the launch of Pervenio Lung RS, a risk stratification molecular test to identify early stage lung cancer patients who are at high risk for mortality following surgery.

Disease recurs in a large percentage of early stage, low-risk patients usually at distant sites. This indicates that the patient harbored metastases that were not detected at the time of surgery. Pervenio Lung RS consists of a quantitative PCR (polymerase chain reaction) assay measuring expression of a proprietary 14-gene panel using formalin-fixed, paraffin-embedded tumor specimens. The prognostic genes are related to known molecular pathways, such as KRAS, BRAF, EGFR, HER2, ALK, and p53

A study published in The Lancet showed the test's clinical validity as a better predictor of mortality than other known risk factors such as sex, smoking history and cell morphology. In addition, results from two independent, blinded retrospective studies studying 1,500 patients also proved the test's validity.

For more information call (888) 734-8588 or visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs